Related Experiment Video

Updated: Aug 17, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

Calcium channel blockers and renal protection: insights from the latest clinical trials

Julián Segura1, José A García-Donaire, Luis M Ruilope

  • 1Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.

Journal of the American Society of Nephrology : JASN
|June 7, 2005
PubMed

Insights

Calcium channel blockers effectively lower blood pressure and protect kidneys in hypertensive patients, including those with chronic kidney disease (CKD). They are a valuable option alone or with other medications.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Hypertension is a major risk factor for chronic kidney disease (CKD).
  • Controlling blood pressure is crucial for preventing renal damage.
  • Metabolic syndrome exacerbates cardiovascular and renal risks.

Purpose of the Study:

  • To evaluate the role of calcium channel blockers in managing hypertension and protecting renal function.
  • To assess the impact of antihypertensive therapies on metabolic alterations.
  • To provide evidence-based recommendations for drug selection in hypertensive patients with or without CKD.

Main Methods:

  • Analysis of data from major clinical trials including IGTHT, ALLHAT, and AASK.
  • Review of antihypertensive drug efficacy and renal protective capacities.
  • Assessment of effects on blood pressure control and metabolic parameters.

Main Results:

  • Calcium channel blockers demonstrate significant antihypertensive efficacy.
  • These agents are effective in preserving renal function in hypertensive individuals.
  • Evidence supports their use in combination with ACE inhibitors or ARBs for enhanced benefits.

Conclusions:

  • Calcium channel blockers are effective antihypertensive agents for patients with preserved renal function or CKD.
  • They can be used as monotherapy or in combination with ACE inhibitors or ARBs.
  • These drugs offer a dual benefit of blood pressure control and kidney protection.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...